Surfactant Deficiency Disorders: SP-B and ABCA3

Author(s):  
Lawrence M. Nogee
1994 ◽  
Vol 29 (12) ◽  
pp. 1634-1636 ◽  
Author(s):  
Hratch L Karamanoukian ◽  
Stuart O'Toole ◽  
Philip L. Glick

1995 ◽  
Vol 78 (5) ◽  
pp. 1800-1805 ◽  
Author(s):  
J. Cifuentes ◽  
J. Ruiz-Oronoz ◽  
C. Myles ◽  
B. Nieves ◽  
W. A. Carlo ◽  
...  

Increased concentrations of partially reduced oxygen and nitrogen reactive species damage the alveolar epithelium and either cause or exacerbate surfactant deficiency. For this reason, there is a quest to identify surfactant replacement mixtures, which in addition to repleting depleted surfactant stores can also reduce the steady-state concentrations of reactive species in the alveolar space. Herein, we evaluated the ability of natural lung surfactant (NLS) and two mixtures (Exosurf and Survanta) used clinically for the correction of surfactant deficiency to scavenge hydroxyl radical-type species (.OH), generated either by the decomposition of peroxynitrite or by Fenton reagents (FeCl3 + H2O2). Exosurf or Survanta decreased .OH only when present at high lipid concentrations (6.5 mM). On the other hand, 40 microM of NLS decreased .OH concentrations from 75 +/- 2 to 53 +/- 2 microM (P < 0.05), most likely because of the interaction of .OH with protein sulfhydryl groups. Similarly, 40 microM of NLS incubated with a bolus of H2O2 (400 microM) decreased the H2O2 concentration in the supernatant by approximately 50%, due to the presence of catalase-type activity. In contrast to NLS, neither Exosurf nor Survanta scavenged H2O2, even when present at millimolar lipid concentrations. We concluded that Exosurf and Survanta contain limited antioxidant activity compared with NLS.


PEDIATRICS ◽  
1980 ◽  
Vol 65 (6) ◽  
pp. 1176-1177
Author(s):  
Mary Ellen Avery

Ever since it was realized that hyaline membrane disease was the consequence of surfactant deficiency, replacing the missing surface-active alveolar lining layer has been a tantalizing prospect. The report of Fujiwara et al1 is the first demonstration in the human of consistent and dramatic success after a single instillation of an artificial surfactant by way of an endotracheal tube. The prompt restoration of a stable alveolar lining layer and the impressive improvement in blood gases are well documented. The problem of the widely patent ductus producing difficulties in the subsequent days is expected and of course could be approached by other interventions.


2014 ◽  
pp. 37-40
Author(s):  
Emily Maduro ◽  
Eric Chong

2017 ◽  
Vol 40 (1) ◽  
pp. 26-30
Author(s):  
Tahsinul Amin ◽  
Mohammod Shahidullah

Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in low birth weight premature infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. Exogenous surfactant therapy has become well established in newborn infants with respiratory distress. Many aspects of its use have been well evaluated in high-quality trials and systematic reviews. Secondary surfactant deficiency also contributes to acute respiratory morbidity in late-preterm and term neonates with meconium aspiration syndrome, pneumonia/ sepsis, and perhaps pulmonary hemorrhage; surfactant replacement may be beneficial for these infants. This article summarizes the evidence and gives recommendations for the use of surfactant therapy for respiratory distress syndrome (RDS) in newborn.Bangladesh J Child Health 2016; VOL 40 (1) :26-30


Respiration ◽  
1996 ◽  
Vol 63 (3) ◽  
pp. 144-149
Author(s):  
Winnie H. Lin ◽  
Joseph G. Turcotte ◽  
Debra Parkinson ◽  
Roger S. Thrall

Sign in / Sign up

Export Citation Format

Share Document